Laia Garrigós

712 total citations · 1 hit paper
35 papers, 402 citations indexed

About

Laia Garrigós is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Laia Garrigós has authored 35 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Laia Garrigós's work include HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (9 papers) and Bone health and treatments (7 papers). Laia Garrigós is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (9 papers) and Bone health and treatments (7 papers). Laia Garrigós collaborates with scholars based in Spain, Portugal and United Kingdom. Laia Garrigós's co-authors include Javier Cortés, María Gión, Miguel Sampayo-Cordero, Marta Vaz Batista, José Manuel Pérez-García, Sofía Braga, Antonio Llombart‐Cussac, María Fernández, Sònia Servitja and Juan de la Haba-Rodríguez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Laia Garrigós

28 papers receiving 395 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

2022 162 citations José Manuel Pérez-García, Marta Vaz Batista et al. Neuro-Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laia Garrigós Spain	9	322	177	63	51	46	35	402
Ferdinand Haslbauer Austria	8	211 0.7×	79 0.4×	38 0.6×	27 0.5×	83 1.8×	26	292
Stefanos Labropoulos Greece	9	201 0.6×	123 0.7×	66 1.0×	28 0.5×	59 1.3×	13	313
Jeffrey C. Goh Australia	11	167 0.5×	91 0.5×	34 0.5×	26 0.5×	109 2.4×	35	376
J P Guastalla France	9	213 0.7×	51 0.3×	84 1.3×	57 1.1×	73 1.6×	14	312
Hak Min Lee South Korea	12	212 0.7×	81 0.5×	79 1.3×	23 0.5×	84 1.8×	32	389
Sarah Morgan United States	6	231 0.7×	108 0.6×	46 0.7×	6 0.1×	150 3.3×	12	421
A. Astone Italy	9	233 0.7×	82 0.5×	32 0.5×	8 0.2×	52 1.1×	22	336
R. Wei United States	8	253 0.8×	129 0.7×	88 1.4×	4 0.1×	23 0.5×	17	328
Stephanie Sutherland United Kingdom	9	203 0.6×	162 0.9×	84 1.3×	20 0.4×	92 2.0×	17	379
Fabio Catalano Italy	11	142 0.4×	119 0.7×	48 0.8×	9 0.2×	61 1.3×	37	329

Countries citing papers authored by Laia Garrigós

Since Specialization

Citations

This map shows the geographic impact of Laia Garrigós's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laia Garrigós with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laia Garrigós more than expected).

Fields of papers citing papers by Laia Garrigós

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laia Garrigós. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laia Garrigós. The network helps show where Laia Garrigós may publish in the future.

Co-authorship network of co-authors of Laia Garrigós

This figure shows the co-authorship network connecting the top 25 collaborators of Laia Garrigós. A scholar is included among the top collaborators of Laia Garrigós based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laia Garrigós. Laia Garrigós is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borrego, Manuel Ruíz, Isabel Blancas, Laia Garrigós, et al.. (2025). 294MO Preoperative window-of-opportunity study with giredestrant or tamoxifen (tam) in premenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) and Ki67≥10% early breast cancer (EBC): The EMPRESS study. Annals of Oncology. 36. S305–S305. 1 indexed citations

Caputo, Mariela, et al.. (2025). Advancing multiplex diagnostics: A novel framework for simultaneous detection of diverse pathogens using respiratory RNA viruses as a model system. Journal of Immunological Methods. 540. 113857–113857.

Cruz, Víctor L., Laura García‐Estévez, José Manuel Pérez-García, et al.. (2025). In silico decrypting of the bystander effect in antibody–drug conjugates for breast cancer therapy. Scientific Reports. 15(1). 28715–28715.

Gión, María, Nuria Ribelles, José Luis Alonso-Romero, et al.. (2025). Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial. Breast Cancer Research. 27(1). 141–141.

Garrigós, Laia, et al.. (2024). Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer. Expert Review of Anticancer Therapy. 24(10). 949–958.

Batista, Marta Vaz, José Manuel Pérez-García, Laia Garrigós, et al.. (2024). Abstract PS11-05: Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study. Cancer Research. 84(9_Supplement). PS11–5. 4 indexed citations

García-Donás, Jesús, Andrés Redondo, Ana Santaballa, et al.. (2024). Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016–01). Gynecologic Oncology. 191. 233–239.

García-Donás, Jesús, Laia Garrigós, Núria Laínez, et al.. (2024). Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01). Clinical & Translational Oncology. 27(7). 3223–3231.

García, José Manuel Pérez, María Gión, Nuria Ribelles, et al.. (2024). Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.. Journal of Clinical Oncology. 42(16_suppl). 1098–1098. 3 indexed citations

10.

Batista, Marta Vaz, José Manuel Pérez-García, Laia Garrigós, et al.. (2024). Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open. 9(9). 103699–103699. 11 indexed citations

11.

Batista, Marta Vaz, José Manuel Pérez-García, Laia Garrigós, et al.. (2024). The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis. Med. 6(1). 100502–100502. 13 indexed citations

12.

Pérez-García, José Manuel, Marta Vaz Batista, Manuel Ruíz Borrego, et al.. (2023). Abstract PD7-02: Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial. Cancer Research. 83(5_Supplement). PD7–2. 6 indexed citations

13.

Pérez-García, José Manuel, Marta Vaz Batista, Manuel Ruíz‐Borrego, et al.. (2022). Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro-Oncology. 25(1). 157–166. 162 indexed citations breakdown →

14.

Pérez, José, Laia Garrigós, María Gión, et al.. (2021). Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Expert Opinion on Biological Therapy. 21(7). 811–824. 24 indexed citations

15.

Ciruelos, Eva, Álvaro Montaño, César A. Rodríguez, et al.. (2020). Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07). European Journal of Cancer Care. 29(4). e13253–e13253. 7 indexed citations

16.

Oliveira, Mafalda, et al.. (2020). Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. Expert Review of Anticancer Therapy. 20(9). 731–741. 7 indexed citations

17.

Prieto‐Alhambra, Daniel, Sònia Servitja, Natalia García‐Giralt, et al.. (2016). AI-related BMD variation in actual practice conditions: A prospective cohort study. Endocrine Related Cancer. 23(4). 303–312. 5 indexed citations

18.

Ciruelos, Eva, Aňa Lluch, Laia Garrigós, et al.. (2016). Abstract OT3-01-03: Phase III clinical trial to evaluate patient's preference for subcutaneous (SC) versus intravenous (IV) trastuzumab administration in patients with HER2 positive, advanced breast cancer (ABC) under IV trastuzumab treatment for at least 4 months and without disease progression. ChangHER-SC study (GEICAM/2012-07). Cancer Research. 76(4_Supplement). OT3–1. 1 indexed citations

19.

Alameda, F., Gemma Mancebo, Laia Garrigós, et al.. (2015). Unusual Presentation of Endometrial Cancer: A Clinicopathological Study of One Case. Open Journal of Obstetrics and Gynecology. 5(1). 23–27. 1 indexed citations

20.

Servitja, Sònia, Xavier Nogués, Daniel Prieto‐Alhambra, et al.. (2011). Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. The Breast. 21(1). 95–101. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact